Coya Therapeutics Inc. (COYA)
COYA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1835022/000119312526107281/0001193125-26-107281-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | COYA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001835022 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $7.9M |
| Net income | -$21.2M |
| Operating income | -$22.6M |
| Net margin | -267.1% |
| Operating margin | -283.9% |
| Revenue growth | +123.6% |
| Cash | $46.8M |
| Total assets | $50.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 8.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result of these conditions, substantial doubt exists about the Company's ability to continue as a going concern." | 10-Q 2026-11-10 |
| Cash and burn | $35.8M cash; operating cash flow -$5.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 23,457,849 (2026-11-05); 20,924,456 a year earlier; 10,030,436 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-05-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Weaver and Tidwell, L.L.P., New York, New York, United States | PCAOB Form AP 2026-03-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $234K | -$10.6M | -$7.2M | $35.8M | No debt tags | $4.7M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $244K | -$6.6M | -$7.4M | $43.2M | No debt tags | $8.0M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $251K | -$7.2M | -$6.2M | $50.7M | No debt tags | $7.9M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $4.0M | -$5.7M | -$1.0M | $46.8M | No debt tags | $7.9M | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | $3.6M | -$2.1M | -$1.1M | $28.1M | No debt tags | $4.0M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $164K | -$6.1M | -$5.8M | $29.8M | No debt tags | $423K | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $258K | -$7.3M | -$2.8M | $35.5M | No debt tags | $3.7M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $2K | -$2.9M | -$2.4M | $38.3M | No debt tags | $3.6M | 10-K 2026-03-16 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-12 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-05-13 |
Source: SEC EDGAR submissions feed, 232 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.7% |
| 1 month | -30.1% |
| 3 months | -33.0% |
| Year to date | -46.0% |
| 1 year | -47.5% |
| From 52-week high | -51.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VTVT | vTv Therapeutics Inc. | $17.69 | -10.16% | $71.0M |
| CRBP | Corbus Pharmaceuticals Holdings Inc. | $3.38 | -0.44% | $69.5M |
| MNOV | Medicinova Inc | $1.34 | -3.94% | $68.7M |
| ZYBT | Zhengye Biotechnology Holding Limited | $1.43 | -4.67% | $67.8M |
| TLSA | Tiziana Life Sciences Ltd. Common Shares | $0.5762 | +1.11% | $73.3M |
| TENX | Tenax Therapeutics Inc. | $1.48 | -8.64% | $67.4M |
| GOSS | Gossamer Bio Inc. | $10.98 | +0.09% | $67.2M |
| KALA | KALA BIO Inc. | $3.83 | -8.02% | $74.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier